The 5 things outside Europe you need to know this week (Samsung $1Bn Biotech IPO, Microbiome blindness, Google Biotech)

Hi there! Here are the 5 most important Biotech things that happened outside Europe in the last few days. 

Enjoy and share!


Samsung, Biogen lining up a $1B IPO for biosimilar joint venture: WSJ

samsung_bioepsis_biogen

ADVERTISEMENT

Samsung is also interested in Biotech and more precisely in Biosimilars. It created a joint-venture with Biogen and now wants to make a $1B IPO with it.

READ MORE ON FIERCE BIOTECH…


New Research Is a Case of the Gut Leading the Blind

microbiome_blindness

[Horai and Zarate-Blades et al./Immunity 2015]

Discoveries in the microbiome field are more and more interesting. Researchers from the NIH even discovered that a form of blindness was caused by gut inflammation due to bacterial infections.

READ MORE ON GENENGNEWS.COM…


Google is doubling down on biotech

google_lens

After announcing Google will now be organized in a holding called Alphabet, co-founder Sergey Brin just announced the creation of a new life science business. It will be run in addition to Calico and will integrate the famous glucose-measuring contact lens as well as many other projects the company has developed inside Google X.

READ MORE ON BUSINESS INSIDER …


Synthetic Biology: the Dawn of a New Era

synthetic_biology

Great article from the HuffPost on analyzing the potential of Synthetic Biology and comparing it with the power of digital technologies. Synthetic Biology is clearly paving the way to so many breakthroughs we can’t even imagine right now.

READ MORE ON HUFFINGTON POST …


Sarepta and BioMarin race for an FDA tag that could be worth $350M-plus

FDA-building

BioMarin and Sarepta are two of the most well funded Biotech companies in the US. They are both developing a drug against the same disease, and they are now fighting to be the first to get market approval.

READ MORE ON FIERCE BIOTECH…

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.